

**2010 Annual Report for Shands
at the University of Florida**
with statistical data from 2009

Message from the Shands at the University of Florida Hospital Cancer Committee Chairman

*Steven Hochwald, MD – Chair
Shands at UF Cancer Committee,
UF College of Medicine Associate Professor and Chief Section of Surgical
Oncology in the Department of Surgery*

The University of Florida Shands Cancer Center (UFSCC) is an interdisciplinary initiative at the UF Health Science Center's Gainesville and Jacksonville campuses, Shands at UF in Gainesville, and Shands Jacksonville. University of Florida clinicians and scientists perform original scientific research and enhance clinical strategies for the diagnosis, treatment and prevention of cancer.

The Shands at UF Cancer Committee is a group of dedicated physicians, nurses and support personnel committed to both the care and treatment of patients. This committee provides the many diverse groups involved in patient-centered cancer care the opportunity to interact, coordinate efforts and establish and maintain the highest quality of service. Meeting quarterly, the committee's goals continue to be that of auditing patient care, assuring the breadth and depth of educational programs, tumor conferences and other clinical activities, ensuring patient access to consultative services in all disciplines and providing oversight and quality control of data from the Oncology Data Center.

The success of the UFSCC and Shands at UF Cancer Program this past year was strengthened by many achievements, which include the following:

2010 Achievements

- The UF Breast Center became the first program in Florida to acquire and use the Intrabeam radiation treatment system, a mobile irradiation device used in the operating room to deliver precise doses of radiation directly to the breast tumor site following surgical removal of the tumor
- UF interventional radiologists are among the first in nation to acquire and use the IRE NanoKnife to precisely deliver electrical currents to destroy tumor cells in patients with cancer
- Ranked in eight specialties in the 2010 edition of American's Best Hospitals, published by U.S. News & World Report and No. 29 in cancer out of nearly 900 cancer hospitals nationwide
- Received \$10.62 million NIH National Institute of General Medicine Sciences grant to study personalized medicine
- Received \$1.52 million NIH grant to investigate the origins of colon cancer, and to explore prevention of benign ulcerative colitis progressing to cancer
- Received a more than \$1.2 million NCI grant to continue research in "The Chemistry and Biology of Largazoles" furthering drug development of a potent anticancer agent discovered from marine microalgae in the Florida Keys by UF researchers
- Received \$1.2 million Bankhead-Coley Florida Cancer Research Program grant to study the development of novel inhibitors that target protein-protein interactions in pancreatic cancer
- Received \$1.2 million Bankhead-Coley Florida Cancer Research Program grant to look at factors involved in treatment decisions made by colorectal cancer patients
- Received \$700,000 National Science Foundation to start a two-year master's program in translational biotechnology, the first of its kind in Florida, preparing graduates for management roles in industry and academia by equipping them with knowledge and skills critical for developing new therapies for use in humans
- Received \$650,000 Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals Inc. grant to begin a new clinical trial in search of a better way to treat patients with advanced, inoperable primary liver cancer who have trouble tolerating standard doses of the only drug available to help them
- Received three U.S. Department of Defense Breast Cancer Concept awards and a \$600,000 research foundation grant to develop new ways to deliver treatment to breast cancer patients
- Received \$500,000 NASCAR Foundation and the V Foundation for Cancer Research grant to fund Shands Children's Hospital's new pediatric cancer unit
- Received \$125,000 Alex's Lemonade Stand Foundation infrastructure grant to help fund an innovative therapy program that will provide treatment options for young patients with rare forms of cancer, or whose families have exhausted all treatment options
- Formed a centralized phone call area for the pelvic floor program to better address patient issues and improve patients' quality of life
- Discovered that dolphins could be ideal model for the study of cervical cancer in people
- Identified new leukemia treatment, Oxi4503, targeting cell growth microenvironment, which poisons leukemia cells and destroys blood vessels supplying them with oxygen and nutrients
- Teamed with Moffitt Cancer Center to study fertility concerns for young cancer patients
- Co-developed and tested the microfluidic cassette, a device that quickly identifies genes and proteins in body fluids at the patient's bedside
- A UF/Shands physician received gubernatorial appointment to serve as chair of the Florida Cancer Control and Research Advisory Council
- Investigating a gene therapy approach to cancer treatment using tiny particles called nano-microspheres that can encapsulate drugs and disperse them throughout a tumor upon injection
- Pioneering a new lung cancer treatment technique, endobronchial intratumoral chemotherapy, that changes the way cancer drugs are administered, minimizing drug toxicity complications

- Conducted, with University of Maryland investigators, a study comparing intensity modulated radiotherapy (IMRT) with proton therapy, showing the latter reducing normal tissue radiation exposure
- Designed and tested versions of a new sensor, possibly providing fresh, inexpensive diagnosis and treatment methods for people suffering from a variety of diseases, including detecting possible indicators of breast cancer in saliva
- Discovered distinct type of virus found in cancer tissue of HIV-positive patients with lymphoma
- Installed Shands Medical Plaza chemistry analyzer, reducing lab wait times
- Obtained HemOnc Clinic and Infusion Center online access to outside lab results
- Created UFSCC ListServe and calendar, providing easy access for posting community events
- Remained the American Cancer Society patient referral leader
- Established an Eastside Clinic American Cancer Society resource center
- Initiated Eastside Clinic Man-to-Man group
- Developed 'Managing Fatigue' patient/family education packet, promoting increased mobility and knowledge of cancer patient exercises
- Hosted and/or participated in on-site, community, and state-wide events:
 - American Cancer Society's Relay for Life
 - Pink Heals Tour 2010
 - American Cancer Society's Making Strides Against Breast Cancer Walk
 - Chords of Color for a Cause – coordinated, in conjunction with UF Performing Arts, a series of five inspiring performing arts events and five lunch-and-learn seminars to raise cancer awareness
 - 40th Annual Radiation Oncology Outcomes Tracking Seminar
 - American Cancer Society CME colorectal seminar
 - Cross City caregiver's conference
 - Nutrition and the Cancer Patient CEU for oncology social workers
 - UF Cancer Survivor Program outreach event
 - Colon cancer and treatment options
 - Lung Cancer and UF thoracic oncology program seminar at Shands Cancer Hospital
 - Oral Cancer Prevention and Screening event at Shands Cancer Hospital
 - Breast Cancer seminar with the UF Breast Center at the Shands Cancer Hospital
 - "Advancing the War on Cancer" outreach reception in West Palm Beach, targeting cancer research and care at UF
 - Bladder Cancer presentation, documentary screening and question and answer event at the Shands Cancer Hospital
 - Minority Cancer Awareness Week, held at various Gainesville locations
 - Annual Prostate Health & Wellness Expo, Martin Luther King, Jr Multipurpose Center, included prostate health screening
- The Villages:
 - Prostate Cancer seminar and screening
 - Liver Cancer Treatment Options seminar with multidisciplinary UF liver team
 - Breast Cancer seminar featuring UF Breast Center team
 - Cancer Center treatment information, clinical programs, and research
 - Three health fairs at the Alachua County School Board with more than 100 in attendance
- Hosted on-going public education forums and initiatives:
 - Ask the Experts – a series of informal discussions on topics important to patients and caregivers
 - Caregiver support groups – informal discussions on topics important to patients and caregivers, held at the Shands Cancer Hospital
 - Shands News (e-format) and News&Notes – electronic and print news media distributed to all Shands HealthCare and UF Health Science Center employees featuring new cancer initiatives, programs, technologies and outreach events.
 - Women's Advantage – monthly seminars on health and lifestyle issues featuring a variety of cancer-related topics and presentations
 - Health In A Heartbeat – two-minute health information segments on 72 national public radio stations in 21 states
 - SUNNA Program targeting low income women
 - Hospice Bereavement Support Group
 - Heads-Up Brain Tumor Support Group
 - American Cancer Society's Look Good – Feel Better monthly event
 - Pet Therapy Program
 - Arts In Medicine Program
- Improved Radiation Oncology outpatient clinic satisfaction score from 92% to 97% excellent rating, receiving a five star IOI award
- Reviewed site-specific cancer program practice profile reports (CP3R) for breast and colorectal cancers and determined that our program fulfills or exceeds all reporting criteria for these indices

2011 Goals

Many cancer program goals continue from year to year. The following lists some of the new, as well as ongoing, goals for the coming year:

- Reduce neutrapenic patient wait times in the E.D.
- Optimize the Shands Pharmacy – EPIC workflow, to reduce inefficiencies with processing prescriptions
- Develop EPIC tumor board templates and more effectively capture and track all cancer patients being treated at UF/Shands
- Develop effective system for communicating upcoming cancer-related events
- Improve CAPS compliance rate

The committee welcomes suggestions for improving the care given to patients with cancer.

Patient Care Evaluation Study

Cancer Program Practice Profile Reports (CP³R) for Colorectal Cancers 2004 - 2007

The University of Florida Shands Hospital Cancer Committee reviewed our institutional data in regards to three parameters associated with quality care in the treatment of patients with colorectal cancer. The years reviewed were 2004-2007.

The parameters reviewed included:

Criteria #1: Adjuvant chemotherapy is considered or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC stage III (lymph node positive) colon cancer.

Our institution was 100% complaint through all the years of the review. This level of compliance compares favorably to other Commission on Cancer approved cancer programs in the state of Florida (71.8% compliant) and for all Commission on Cancer approved cancer programs (82.5% compliant).

Criteria #2: At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.

Our institution was 100% compliant through the first two years (2004 and 2005) and then 58.3% and 74.1% compliant for 2006 and 2007, respectively. The reason for the decrease in compliance for 2006 and 2007 is not clear but there has been considerable emphasis placed on the adequate operative removal of lymph nodes and appropriate pathologic analysis of resected colon cancer specimens. These issues are discussed at our weekly Gastrointestinal Tumor conference. Our data from 2004-2007 has been compared to other Commission on Cancer approved institutions in Florida and throughout the country. Our overall compliance (74.1%) during this time frame was similar to other institutions in Florida (75.3 compliance) and throughout the country (75.2% compliance). Of note, our institution has demonstrated sustained improvements in lymph node retrieval for 2008. A preliminary analysis of our institutional data indicates a 88.2% compliance with this criteria in 2008.

Criteria #3: Radiation therapy is considered or administered within 6 months (180 days) of diagnosis for patients under the age of 80 with clinical or pathologic AJCC T4N0M0 or stage III receiving surgical resection for rectal cancer.

Our institution was 100% complaint through all the years of the review. This level of compliance compares favorably to other Commission on Cancer approved cancer programs in the state of Florida (84.2%) and throughout the country (87.4%).

In summary, a profile of our cancer program practice in regards to colorectal cancer for 2004-2007 reveals excellence compliance with quality measures.

2009 Primary Site Table

Primary Site	Total	Percent (%)	Class		M	Sex	
			A	N/A		F	
ALL SITES	2914	100	2321	593	1578	1336	
ORAL CAVITY	136	4.7%	126	10	91	45	
LIP	5	0.2%	5	0	4	1	
TONGUE	41	1.4%	38	3	26	15	
OROPHARYNX	8	0.3%	6	2	5	3	
HYPOPHARYNX	1	0.0%	1	0	1	0	
OTHER	81	2.8%	76	5	55	26	
DIGESTIVE SYSTEM	472	16.2%	397	75	284	188	
ESOPHAGUS	41	1.4%	36	5	31	10	
STOMACH	28	1.0%	24	4	21	7	
COLON	96	3.3%	61	35	50	46	
RECTUM	50	1.7%	42	8	32	18	
ANUS/ANAL CANAL	19	0.7%	15	4	4	15	
LIVER	102	3.5%	91	11	71	31	
PANCREAS	84	2.9%	82	2	46	38	
OTHER	52	1.8%	46	6	29	23	
RESPIRATORY SYSTEM	294	10.1%	260	34	177	117	
NASAL/SINUS	17	0.6%	17	0	10	7	
LARYNX	40	1.4%	38	2	34	6	
LUNG/BRONCHUS	229	7.9%	197	32	125	104	
OTHER	8	0.3%	8	0	8	0	
BLOOD & BONE MARROW	195	6.7%	120	75	105	90	
LEUKEMIA	104	3.6%	72	32	56	48	
MULTIPLE MYELOMA	62	2.1%	32	30	31	31	
OTHER	29	1.0%	16	13	18	11	
BONE	47	1.6%	29	18	29	18	
CONNECT/SOFT TISSUE	93	3.2%	72	21	52	41	
SKIN	155	5.3%	121	34	96	59	
MELANOMA	117	4.0%	105	12	74	43	
OTHER	38	1.3%	16	22	22	16	
BREAST	217	7.4%	182	35	0	217	
FEMALE GENITAL	183	6.3%	142	41	0	183	
CERVIX UTERI	34	1.2%	33	1	0	34	
CORPUS UTERI	57	2.0%	53	4	0	57	
OVARY	54	1.9%	36	18	0	54	
VULVA	29	1.0%	17	12	0	29	
OTHER	9	0.3%	3	6	0	9	
MALE GENITAL	225	7.7%	177	48	225	0	
PROSTATE	205	7.0%	160	45	205	0	
TESTIS	18	0.6%	15	3	18	0	
OTHER	2	0.1%	2	0	2	0	
URINARY SYSTEM	299	10.3%	231	68	220	79	
BLADDER	120	4.1%	84	36	98	22	
KIDNEY/RENAL	163	5.6%	133	30	111	52	
OTHER	16	0.5%	14	2	11	5	
BRAIN & CNS	248	8.5%	213	35	118	130	
BRAIN (BENIGN)	15	0.5%	15	0	9	6	
BRAIN (MALIGNANT)	93	3.2%	83	10	58	35	
OTHER	140	4.8%	115	25	51	89	
ENDOCRINE	151	5.2%	117	34	69	82	
THYROID	57	2.0%	47	10	20	37	
OTHER	94	3.2%	70	24	49	45	
LYMPHATIC SYSTEM	131	4.5%	88	43	73	58	
HODGKIN'S DISEASE	20	0.7%	13	7	14	6	
NON-HODGKIN'S	111	3.8%	75	36	59	52	
UNKNOWN PRIMARY	44	1.5%	33	11	27	17	
OTHER/ILL-DEFINED	24	0.8%	13	11	12	12	

Number of cases excluded: 0 This report INCLUDES CA in-situ cervix cases, squamous and basal cell skin cases, and intraepithelial neoplasia cases.

KEY:

Analytic = Cases diagnosed and/or receiving all or part of the initial course of therapy at the UF Shands Cancer Center

Non-Analytic = Cases diagnosed and/or receiving all of the first course of therapy elsewhere; cases initially diagnosed at autopsy

Shands at the University of Florida Oncology Data Center

The Oncology Data Center is an essential part of the hospital cancer program, functioning within the guidelines of the American College of Surgeons-Commission on Cancer (ACOS-COC) approvals program. The Oncology Data Center collects data on all cancer cases diagnosed and/or treated at Shands at the University of Florida in Gainesville.

Since Shands at UF opened in 1958, the Oncology Data Center has accrued more than 83,000 new cancer cases, making it one of the largest registries in the state of Florida. More than 2,900 cases are added each year. The revised ACOS-COC 1998 reference date reflects a caseload of greater than 27,000, with more than 10,000 being followed annually.

The Oncology Data Center is fully computerized and provides data pertinent to the diagnosis, treatment and survival of patients with malignant and selected pre-malignant tumors. This information is available to medical staff, residents and medical students for research analysis, and to administration for statistical data reflecting the cancer experience at Shands at UF. The data may be used to:

- Identify cases meeting certain criteria for physicians and other investigators
- Provide follow-up information on cancer patients for evaluation of patient care, treatment, survival and early detection of recurrent disease
- Calculate survival rates by site, stage of disease, sex and other variables
- Analyze referral patterns of cancer patients to identify needs for future healthcare facilities

Requests for data are welcomed and should be directed to:

Shands at UF Oncology Data Center
PO Box 100342 • Gainesville, Florida 32610-0342
(352) 265-0740 – phone • (352) 265-0748 – fax
or, emailed to Anne Tallent at tallent@shands.ufl.edu

Data requests which include the need for patient identifying data (PID) require appropriate IRB approval documentation.

In addition to maintaining the hospital's oncology database, the Oncology Data Center participates in several external oncology-related activities including:

- The National Cancer Database (NCDB) – A joint venture of the ACOS-COC and the American Cancer Society (ACS), this database collects and analyzes longitudinal data regarding cancer patient care at the hospital, regional, state and national levels. Each year the Oncology Data Center submits data electronically in a format compatible with the national database.
- The American Cancer Society Facility Information Profile System (FIPS) – The ACS has established a national call center Web site to provide cancer patients, their families and the public with information about cancer. Included is hospital-specific information about the availability and quality of cancer care in local communities. A link is provided to each hospital's Web site. Updates to hospitals' services, statistical data and contact information are made as needed.
- The Florida Cancer Data System (FCDS) – Under Florida law, all healthcare facilities are required to submit incidence data on all cases of cancer treated at their sites. For patients seen at Shands at UF, the Oncology Data Center electronically reports all accessioned cases of cancer to the state on a monthly basis.
- The Florida Association of Pediatric Tumor Programs, Inc. (FAPTP) – The major hematology/oncology centers in Florida participate in the Statewide Patient Information Reporting System (SPIRS) registry of FAPTP. SPIRS provides the only statewide cancer registry focused on pediatrics.

Shands at the University of Florida 2010 Hospital Cancer Committee

Robert Allan, MD..... UF College of Medicine associate professor in the department of Pathology

Suzanne Bird, RD, LD/NFood and Nutrition Services

Shirley Bloodworth, RN, BSN, MN.....Patient Advocate

Colleen Booker, RN, BSN GI Oncology Center

Byron P. Croker, MD, PhD UF College of Medicine associate professor in the department of Pathology

Karen Daily, DO UF College of Medicine fellow in the department of Hematology/Oncology

Erin McQ. Dunbar, MD... UF College of Medicine associate professor in the department of Neuro-Oncology

Thomas George, MD..... UF College of Medicine associate professor in the department of Hematology/Oncology

Scott Gilbert, MDUF College of Medicine professor in the department of Urology

Kati Harlan, RN, MSN, LRHM Quality Management

Steven Hochwald, MD... UF College of Medicine associate professor in the department of Surgery, Cancer Committee Chair, Cancer Liaison Physician

Marcia Hodge, CTR..... Oncology Data Center

Robert W. Hurley, MD, PhDUF College of Medicine professor in the department of Anesthesiology

Frederic Kaye, MD UF College of Medicine associate professor in the department of Hematology/Oncology

Judith Lightsey, MD..... UF College of Medicine associate professor in the department of Radiation Oncology

Kevin McDonald, PTRehabilitative Services

Gigi Moore-Higgs, ARNP, PhD(c), AOCNUFSCC Clinical Trials Office

Linda S. Morgan, MDUF College of Medicine professor in the department of Obstetrics and Gynecology, Oncology Data Center Medical Director

Patricia Moser, MD UF College of Medicine associate professor in the department of Radiology

Paul Okunieff, MD Director, UF&Shands Cancer Center, UF College of Medicine Chair, Dept. of Radiation Oncology

Nina Powell, LCSW ..Patient and Family Resources/Patient Services

Andrew Ragsdale.....Shands HealthCare Marketing and Public Relations

Maryam Rahman, MD Neurosurgery Residency Program

Steve Ritz..... Administration/Radiation Oncology

Mark Scarborough, MD. UF College of Medicine associate professor in the department of Orthopedics

Patricia Shearer, MDUFSCC Cancer Survivor Program

Donald Shook Administration/Operations

Gale Smith, LCSW Patient and Family Resources/Patient Services

Lee Starling, RHITHealth Information and Record Management

Bruce Stechmiller, MD... UF College of Medicine associate professor in the department of Hematology/Oncology

James L. Talbert, MD..... UF College of Medicine professor emeritus in the department of Surgery

Anne M. Tallent, CTR..... Oncology Data Center

Mel Toran.....American Cancer Society

Glenn E. Turner, DDSUF College of Dentistry associate professor in the department of Prosthodontics

Helen Welsh, BSN, RN.....Nursing

Laura Wiggins, PharmD.....Pharmacy Services

Fong Wong, DDSUF College of Dentistry associate professor in the department of Prosthodontics

Narrative Summary of 2009 Data

The Shands at the University of Florida Oncology Data Center has analyzed data for all patients with reportable disease first seen at UF Shands Cancer Center between January 1, 2009 and December 31, 2009. During that time, 2,914 new cases were diagnosed and/or treated here as either inpatients, outpatients, or both. Of these cases, 2,321 were analytic (80%) meaning they received all or part of their first course of treatment at our facility. The remaining 593 cases (20%) were non-analytic, meaning patients were diagnosed and received their entire initial course of therapy elsewhere. The total new cases volume increased by 4% from 2008, and 1% for analytic cases. Increases were noted in several overall and analytic site groups. Among them is breast (31% - overall, 27% - analytic). This increase is attributed to efforts of achieving NAPBC (National Accreditation Program for Breast Centers) accreditation by the American College of Surgeons - Commission on Cancer. The program was awarded a Three-Year Full Accreditation in 2010. Urinary system, also, saw an increase (22% - overall, 21% - analytic). This is credited in part to continued efforts in developing the Genitourinary Oncology Center.

Top Sites

Increases were seen in numerous sites. Primary sites with the highest new cases volume overall were anus/anal canal and cervix uteri (47% each), breast (31%), ovary (26%), Hodgkin's disease (25%), vulva (24%), and kidney/renal (21%). The rise in GYN cases justified the addition of one physician in 2010.

Service Area

Holding to our customary patterns, individuals from virtually every county in the State of Florida continued to seek care at the UF Shands Cancer Center. Individuals residing in counties of the North Central Florida and North East Florida areas comprised 50% (1,456) of the total new cases in 2009. This is an 6% increase from 2008. Figures from the top individual counties reflect the following: Alachua - 545 (19%), Marion - 325 (11%), Out-of-State - 162 (6%), Citrus - 123 (4%), and Lake - 113 (4%), and Columbia - 111 (4%) with a combined 1,379 (47%).

Gender/Race/Ethnicity/Age

Cases for females totaled 1,336, or 46%. Cases for males totaled 1,578, or 54%. The female group increased by 10%, and the males increased by .03% from 2008 figures.

New Cancer Cases

KEY:

These estimates are offered as a rough guide. They are calculated according to the distribution of estimated new cancer cases by state for the year 2010. These figures were obtained from the 2010 Cancer Facts & Figures, published by the American Cancer Society.

Excludes basal and squamous cell skin cancers and in-situ carcinomas (except urinary bladder).

***Shands at UF's figures were obtained from the total number of accessioned cases at Shands at UF during 2009.*

United States, Florida, and Shands at the University of Florida

PRIMARY SITE	UNITED STATES*	FLORIDA*	SHANDS AT UF**
BREAST (FEMALE)	207,090	14,080	217
	13.5%	13.2%	7.4%
LUNG	222,520	18,390	229
	14.5%	17.2%	7.9%
PROSTATE	217,730	14,610	205
	14.2%	13.7%	7.0%
COLORECTAL	142,570	10,500	146
	9.3%	9.8%	5.0%
BLADDER	70,530	5,600	120
	4.6%	5.2%	4.1%
NON-HODGKIN LYMPHOMA	65,540	4,660	111
	4.3%	4.4%	3.8%
CORPUS UTERI	43,470	2,710	57
	2.8%	2.5%	2.0%
MELANOMA	68,130	4,980	117
	4.5%	4.7%	4.0%
LEUKEMIA	43,050	3,330	104
	2.8%	3.1%	3.6%
CERVIX	12,200	940	34
	0.8%	0.9%	1.2%
ALL OTHERS	436,730	27,350	1,574
	28.6%	25.6%	54.0%
TOTAL CASES	1,529,560	107,000	2,914
	100%	100%	100%

Top Sites: Reportable, Analytic Cases (AJCC/TNM Staging)

	TOTAL	0	I	II	III	IV	UNKNOWN	N/A
BRAIN/CNS	213	0	0	0	0	0	0	213
LUNG/BRONCHUS	197	0	30	7	43	108	8	1
BREAST	182	33	61	23	14	11	39	1
PROSTATE	160	0	1	126	18	12	3	0
KIDNEY/RENAL	133	2	55	10	16	17	32	1
TOTALS	885	35	147	166	91	148	82	216

Geographic Distribution by County

ALACHUA	545	HERNANDO	15	PALM BEACH	23
BAKER	7	HIGHLANDS	5	PASCO	9
BAY	45	HILLSBOROUGH	14	PINELLAS	23
BRADFORD	45	HOLMES	4	POLK	16
BREVARD	89	INDIAN RIVER	20	PUTNAM	89
BROWARD	9	JACKSON	14	ST. JOHNS	44
CALHOUN	4	JEFFERSON	7	ST. LUCIE	37
CHARLOTTE	5	LAFAYETTE	10	SANTA ROSA	10
CITRUS	123	LAKE	113	SARASOTA	11
CLAY	66	LEE	10	SEMINOLE	27
COLLIER	4	LEON	89	SUMTER	85
COLUMBIA	111	LEVY	99	SUWANNEE	78
DADE	2	LIBERTY	1	TAYLOR	15
DIXIE	26	MADISON	9	UNION	27
DUVAL	86	MANATEE	8	VOLUSIA	89
ESCAMBIA	25	MARION	325	WAKULLA	10
FLAGLER	17	MARTIN	12	WALTON	14
FRANKLIN	4	MONROE	2	WASHINGTON	6
GADSDEN	11	NASSAU	7	OUT OF STATE	162
GILCHRIST	34	OKALOOSA	23	OUT OF COUNTRY	11
GULF	4	OKEECHOBEE	4	OVERALL TOTALS	2914
HAMILTON	24	ORANGE	43		
HARDEE	1	OSCEOLA	7		

Ten Most Frequent Malignant Sites

SITE	COUNT
Lung/Bronchus	229
Breast	217
Prostate	205
Kidney/Renal	163
Colorectal	146
Oral cavity	135
Bladder	120
Melanoma	117
Non-Hodgkin's Lymphoma	111
Leukemia	104
All other sites	1,066
Total	2,613

